Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study

Liang, Xiao; Xu, Xiaoqing; Zheng, Qing; Zhang, Wei; Sun, Qin-Juan; Liu, Wenzhong; Xiao, Shu–Dong; Lü, Hong

doi:10.1016/j.cgh.2013.01.008

Cited by 142 publications

(147 citation statements)

References 22 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Bismuth-containing quadruple therapy is an alternative to standard triple therapy in areas with low clarithromycin resistance and the main first-line therapeutic option in areas with high prevalence of clarithromycin resistance. Using this regimen at full doses for 14 d produces a 95% or greater treatment success rate, irrespective of the level of metronidazole resistance [117] .…”

Section: Bismuth-based Quadruple Therapymentioning

confidence: 98%

Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens

Chang¹,

Hu²

2015

WJGPT

View full text Add to dashboard Cite

show abstract

Section: Bismuth-based Quadruple Therapymentioning

confidence: 98%

Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens

Chang¹,

Hu²

2015

WJGPT

View full text Add to dashboard Cite

show abstract

“…The presence of bismuth compounds in this combination has a mucosal cytoprotective and ulcer healing effects, and in addition, it has some complex actions on H. pylori, such as inhibition of adenosine triphosphat and protein synthesis and membrane function, and can suppress H. pylori in vivo when they are used alone [80]. However, their combination with two antibiotics significantly increases their efficacy on H. pylori and may overcome antibiotic resistance [81,82]. As mentioned earlier, the strong association of blood Group O with H. Pylori infection may explain the higher eradication rate with bismuth-containing H. pylori eradication regimen compared to the lower eradication rate with triple therapy.…”

Section: Ulcer Healing Efficacy Of Standard Triple and Quadruple H Pmentioning

confidence: 99%

Clinical Evaluation of Triple and Quadruple Helicobacter Pylori Eradication Therapy in Peptic Ulcer Patients With Different Abo Blood Group Phenotypes

Abdulridha

Kutaif

Kamal

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: This study aimed to examine the pathological changes in gastric mucosa of Helicobacter pylori-infected peptic ulcer patients carrying different ABO phenotypes and to study the response to the 14 days' standard triple therapy and 10 days' quadruple therapy in peptic ulcer patients according to their ABO phenotypes. Methods:Interventional prospective randomized-controlled open-label study was performed on newly diagnosed patients with PUD. The H. pyloripositive patients were allocated into two major study groups in which they are subdivided according to ABO blood group phenotypes: Group 1 received standard H. pylori eradication triple therapy and Group 2 received standard H. pylori eradication quadruple regimen. Patients were monitored after 2 months for successful H. pylori eradication.Results: Chronic active gastritis was significantly high in patients carrying blood Group O phenotype (81.25%), while the atrophic gastritis and intestinal metaplasia were significantly high in patients carrying blood Group A phenotype (25.00% and 16.67%), respectively. 14 days' triple therapy showed significantly lower eradication rate in H. pylori-infected peptic ulcer patients carrying blood Group O phenotype (p<0.01), meanwhile higher response was found among patients with blood Group B. 10 days' quadruple therapy produced a significant high eradication rate in H. pylori-infected patients carrying blood Group O than those with blood Group A (p<0.01), but still both showed lower response compared to that in patients carrying blood Group B and AB phenotypes. Elderly patients showed significantly less healing efficacy than younger patients (p<0.01), and the least healing rate was noticed in female patients after both regimens. Conclusion:Lower eradication rate in H. pylori-infected was noticed in peptic ulcer patients carrying blood Group O mainly than those with other blood groups and particularly those with duodenal Ulceri. 10 days' quadruple therapy showed significant higher eradication rate in H. pylori infection and a better ulcer healing efficacy.

show abstract

“…Recent studies conducted in Italy and China have shown similar success rates using twice-a-day bismuth and full 4-times-a-day antibiotic doses. 57,58 In this context, bismuth-based quadruple therapy in its most recent galenic formulation, bismuth subcitrate potassium, metronidazole, and tetracycline (bismuth, metronidazole and tetracycline [BMT], sold under license as Pylera), may be an attractive therapeutic option. 7 However, its use is currently limited by its high cost, the fact that only a 10-day regimen is available in a prepackaged form, and the dose of tetracycline is only 1500 mg.…”

Section: Bismuth Quadruple Therapymentioning

confidence: 99%

Practical Aspects in Choosing a Helicobacter pylori Therapy

Molina–Infante

Shiotani

2015

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study

Cited by 142 publications

References 22 publications

Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens

Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens

Clinical Evaluation of Triple and Quadruple Helicobacter Pylori Eradication Therapy in Peptic Ulcer Patients With Different Abo Blood Group Phenotypes

Practical Aspects in Choosing a Helicobacter pylori Therapy

Contact Info

Product

Resources

About